Cas no 191732-72-6 (Lenalidomide)
Lenalidomide Chemical and Physical Properties
Names and Identifiers
-
- Lenalidomide
- 3-(7-amino-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione
- LenalidomideLenalidomide
- 1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
- 3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
- CC-5013
- Revlimi
- Lenalidomide(other anti-cancers)
- (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
- 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
- 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
- Lenalidomide (CC-5013)
- Lenalidomide (CC-5013, Revlimid?)
-  
- Arava
- CC5013
- Faslodex
- Fulvestrant
- HWA 486
- ICI182780
- Leflunomid
- Leflunomida
- Leflunomide
- Leflunomidum
- lefunamide
- ZD9238
- ZM182780
- 1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole
- 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
- E3 Ligase ligand
- 3-(4-Amino-1-oxoisoindolin-2-yl)piperidin-2,6-dione
- Revlimid
- To the amine
- LenalidoMide-d5
- LenalidoMide (RevliMid)
- CC 5013
- Lenalidomide ,98%
- SGT67 [email protected]
- Revimid
- IMiD3
- CDC 501
- Revlimid (lenalidomide)
- 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-
- Revlimid (TN)
- 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
- DSSTox_RID_
- GTPL7331
- LENALIDOMIDE [MART.]
- NCGC00167491-04
- BCPP000186
- SW218084-2
- AC-914
- BL164614
- LENALIDOMIDE [WHO-DD]
- 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine
- CDC-501
- Lenadoamide
- Z1515385074
- SR-01000883999
- IMID-5013
- AB01273975_03
- MFCD07772307
- NSC-747972
- CAS-191732-72-6
- DTXSID8046664
- BCP01390
- Tox21_112492_1
- AKOS005146276
- BP-27972
- Lenalidomida
- Q425681
- HMS3674C05
- Q-101410
- 191732-72-6
- MLS003899194
- 443912-14-9
- FT-0670759
- 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione
- ENMD-0997
- LENALIDOMIDE [ORANGE BOOK]
- 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione
- KS-1207
- LENALIDOMIDE [VANDF]
- HMS3654G07
- Lenalidomide (USAN/INN)
- GOTYRUGSSMKFNF-UHFFFAOYSA-N
- UNII-F0P408N6V4
- Tox21_112492
- DTXCID6026664
- 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-
- AKOS005174869
- Revlimid (TN) (Celgene)
- AB01273975-02
- lenalidomidum
- AM20050439
- SB66166
- D04687
- NCGC00167491-03
- NSC747972
- NSC 747972
- HY-A0003
- BCP9000847
- LENALIDOMIDE [MI]
- Revlimid, Lenalidomide, CC-5013
- Lenalidomide [USAN]
- 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione
- IMiD3 cpd
- NS00003666
- SY047646
- BDBM65454
- 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-
- 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one
- HSDB 8220
- LENALIDOMIDE (MART.)
- L04AX04
- LENALIDOMIDE [JAN]
- AB01273975-01
- NCGC00167491-01
- SMR002529986
- FT-0659651
- CHEBI:63791
- CCG-264781
- Lenalidomide [USAN:INN:BAN]
- SYP-1512
- NSC703813
- LENALIDOMIDE [EMA EPAR]
- CHEMBL848
- SR-01000883999-1
- SCHEMBL32978
- CDC-5013
- FT-0670758
- NCGC00167491-02
- EN300-118706
- CS-0125
- s1029
- ENMD 0997
- DB00480
- (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
- F0P408N6V4
- C13H13N3O3
- LENALIDOMIDE [INN]
- SCHEMBL1980410
- SCHEMBL26646478
- BRD-A17883755-001-06-1
- ALBB-015321
- STK639603
- Lenalidomide?
- Lenalidomide (JAN/USAN/INN)
-
- MDL： MFCD07772307
- Inchi： 1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
- InChI Key： GOTYRUGSSMKFNF-UHFFFAOYSA-N
- SMILES： O=C1C2C=CC=C(C=2CN1C1C(NC(CC1)=O)=O)N
Computed Properties
- Exact Mass: 259.09600
- Monoisotopic Mass: 259.096
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 19
- Rotatable Bond Count: 1
- Complexity: 437
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 8
- XLogP3: -0.5
- Topological Polar Surface Area: 92.5
Experimental Properties
- Color/Form: Powder
- Density: 1.46
- Melting Point: 265-268 ?°C
- Boiling Point: 614°C at 760 mmHg
- Flash Point: 325.1 °C
- Refractive Index: 1.672
- PSA: 92.50000
- LogP: 0.87770
Lenalidomide Security Information
- Signal Word：Warning
- Hazard Statement： H302-H315-H319-H335
- Warning Statement： P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
- Hazard Category Code： 20/21/22
- Safety Instruction： S26; S36
-
Hazardous Material Identification：
- HazardClass：IRRITANT
- Storage Condition：2-8°C
- Risk Phrases：R36/37/38
Lenalidomide Customs Data
- HS CODE：2925190090
- Customs Data：
China Customs Code:
2925190090Overview:
2925190090 Other imides and their derivative salts. VAT:17.0% Tax refund rate:9.0% Regulatory conditions:nothing MFN tariff:6.5% general tariff:30.0%
Declaration elements:
Product Name, component content, use to
Summary:
2925190090 other imides and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%
Lenalidomide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | L0332-1G |
Lenalidomide |
191732-72-6 | >98.0%(HPLC) | 1g |
￥1950.00 | 2023-09-07 | |
| Fluorochem | 078933-1g |
Lenalidomide |
191732-72-6 | 95% | 1g |
￡47.00 | 2022-03-01 | |
| Fluorochem | 078933-5g |
Lenalidomide |
191732-72-6 | 95% | 5g |
￡148.00 | 2022-03-01 | |
| Fluorochem | 078933-10g |
Lenalidomide |
191732-72-6 | 95% | 10g |
￡236.00 | 2022-03-01 | |
| Fluorochem | 078933-25g |
Lenalidomide |
191732-72-6 | 95% | 25g |
￡420.00 | 2022-03-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L125046-5g |
Lenalidomide |
191732-72-6 | ≥99% | 5g |
￥259.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L125046-250mg |
Lenalidomide |
191732-72-6 | ≥99% | 250mg |
￥30.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L125046-50mg |
Lenalidomide |
191732-72-6 | ≥99% | 50mg |
￥29.90 | 2023-09-02 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | L125046-1g |
Lenalidomide |
191732-72-6 | ≥99% | 1g |
￥74.90 | 2023-09-02 | |
| AstaTech | 21434-1/G |
LENALIDOMIDE |
191732-72-6 | 97% | 1g |
$10 | 2023-09-18 |
Lenalidomide Suppliers
Audited Supplier
Audited Supplier
Audited Supplier
Lenalidomide Related Literature
-
Chaoguo Cao,Ming He,Liguo Wang,Yuna He,Yu Rao Chem. Soc. Rev. 2022 51 7066
-
Izidor Sosi?,Ale?a Bricelj,Christian Steinebach Chem. Soc. Rev. 2022 51 3487
-
Zhi Lin,Christina M. Woo Chem. Soc. Rev. 2022 51 7115
-
Ke Li,Craig M. Crews Chem. Soc. Rev. 2022 51 5214
-
Ke Li,Craig M. Crews Chem. Soc. Rev. 2022 51 5214
Additional information on Lenalidomide
Lenalidomide (CAS No. 191732-72-6): A Comprehensive Overview
Lenalidomide (CAS No. 191732-72-6) is a derivative of thalidomide, a small molecule immunomodulatory drug (IMiD) that has gained significant attention in the field of oncology and hematology. This compound is widely recognized for its therapeutic potential in treating multiple myeloma, myelodysplastic syndromes (MDS), and other hematological malignancies. The unique properties of lenalidomide make it a valuable addition to the arsenal of drugs used in the management of these conditions.
The chemical structure of lenalidomide is characterized by a substituted phthalimide ring, which confers its immunomodulatory and anti-inflammatory properties. These properties are crucial for its efficacy in various clinical settings. The mechanism of action of lenalidomide involves multiple pathways, including the modulation of cytokine production, enhancement of T-cell and natural killer (NK) cell activity, and inhibition of angiogenesis. These mechanisms collectively contribute to its antitumor effects and make it a versatile therapeutic agent.
In the context of multiple myeloma, lenalidomide has been shown to significantly improve patient outcomes when used in combination with other therapies such as dexamethasone. Clinical trials have demonstrated that this combination therapy can achieve high response rates and prolong progression-free survival (PFS) and overall survival (OS). The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have approved lenalidomide for use in multiple myeloma, particularly in relapsed or refractory cases.
Beyond multiple myeloma, lenalidomide has also shown promise in the treatment of myelodysplastic syndromes (MDS), particularly those associated with a deletion 5q cytogenetic abnormality. In patients with del(5q) MDS, lenalidomide has been effective in reducing red blood cell transfusion dependence and improving overall quality of life. The FDA has approved lenalidomide for this indication based on robust clinical data demonstrating its efficacy and safety.
The safety profile of lenalidomide is an important consideration in its clinical use. Common side effects include neutropenia, thrombocytopenia, fatigue, and rash. However, these adverse events are generally manageable with appropriate monitoring and dose adjustments. To mitigate the risk of teratogenicity, which is a known side effect of thalidomide derivatives, strict risk management programs are in place to ensure that patients understand the potential risks and take necessary precautions.
In recent years, research has expanded to explore the potential applications of lenalidomide in other areas beyond hematological malignancies. Studies have investigated its use in solid tumors such as multiple sclerosis, lupus erythematosus, and chronic lymphocytic leukemia (CLL). Preliminary results from these studies suggest that lenalidomide may have broader therapeutic applications due to its immunomodulatory properties.
The pharmacokinetics of lenalidomide have been well-characterized through extensive clinical studies. It is rapidly absorbed after oral administration, with peak plasma concentrations typically achieved within 1-2 hours. The drug has a relatively short half-life, which allows for once-daily dosing. Metabolism primarily occurs via non-enzymatic hydrolysis to an inactive metabolite, which is then excreted renally.
In conclusion, lenalidomide (CAS No. 191732-72-6) is a potent immunomodulatory drug with significant therapeutic potential in the treatment of multiple myeloma, myelodysplastic syndromes, and other hematological malignancies. Its unique mechanism of action and favorable safety profile make it an essential component of modern cancer therapy. Ongoing research continues to explore new applications and combinations involving lenalidomide, further solidifying its position as a cornerstone treatment in oncology and hematology.
191732-72-6 (Lenalidomide) Related Products
- 304-17-6(N-Isopropylphthalimide)
- 1515-72-6(N-Butylphthalimide)
- 77-86-1(Tris(hydroxymethyl)aminoethane)
- 50-35-1(Thalidomide)
- 340-90-9(N-Phthaloyl-L-glutamic Acid)
- 550-44-7(2-Methylisoindole-1,3-dione)
- 51-06-9(Procainamide)
- 19171-19-8(Pomalidomide)
- 164656-23-9(Dutasteride)
- 497147-11-2(N-Hydroxy Pomalidomide)
